Chi Sheng Pharma & Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Chi Sheng Pharma & Biotech has a total shareholder equity of NT$1.2B and total debt of NT$130.0M, which brings its debt-to-equity ratio to 10.5%. Its total assets and total liabilities are NT$1.8B and NT$533.8M respectively. Chi Sheng Pharma & Biotech's EBIT is NT$51.4M making its interest coverage ratio -3.3. It has cash and short-term investments of NT$379.7M.
Key information
10.5%
Debt to equity ratio
NT$130.00m
Debt
Interest coverage ratio | -3.3x |
Cash | NT$379.69m |
Equity | NT$1.24b |
Total liabilities | NT$533.83m |
Total assets | NT$1.78b |
Recent financial health updates
No updates
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Financial Position Analysis
Short Term Liabilities: 4111's short term assets (NT$809.6M) exceed its short term liabilities (NT$436.3M).
Long Term Liabilities: 4111's short term assets (NT$809.6M) exceed its long term liabilities (NT$97.5M).
Debt to Equity History and Analysis
Debt Level: 4111 has more cash than its total debt.
Reducing Debt: 4111's debt to equity ratio has increased from 1.9% to 10.5% over the past 5 years.
Debt Coverage: 4111's debt is well covered by operating cash flow (36.2%).
Interest Coverage: 4111 earns more interest than it pays, so coverage of interest payments is not a concern.